Scinai Immunotherapeutics (SCNI) Current Assets (2017 - 2026)
Scinai Immunotherapeutics (SCNI) posted Current Assets of $3.6 billion for Q1 2026, up 75.95% sequentially from $2.1 billion in Q4 2025.
Scinai Immunotherapeutics (SCNI) Current Assets (2017 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Current Assets for 10 years, with the latest figure at $3.6 billion in Q1 2026.
- Quarterly Current Assets changed N/A year-over-year to $3.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (changed N/A YoY) and the FY2025 annual result came in at $2.1 billion, up 85805.48% from the prior year.
- Current Assets improved to $3.6 billion in Q1 2026 per SCNI's latest filing, from $2.1 billion in the prior quarter.
- Over five years, Current Assets peaked at $3.6 billion in Q1 2026 and troughed at $1.5 million in Q2 2025.
- A 5-year average of $410.6 million and a median of $7.2 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets plunged 75.91% in 2024, then jumped 85805.48% in 2025.
- Over 5 years, Current Assets stood at $14.4 million in 2022, then slumped by 62.09% to $5.4 million in 2023, then slumped by 56.1% to $2.4 million in 2024, then surged by 85805.48% to $2.1 billion in 2025, then surged by 75.95% to $3.6 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $3.6 billion, $2.1 billion, and $1.5 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Scinai Immunotherapeutics | 1.08 Mn | -3.11 Bn | -1.12 Mn | 3.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.61 Bn |
| Dec 31, 2025 | 2.05 Bn |
| Jun 30, 2025 | 1.51 Mn |
| Dec 31, 2024 | 2.39 Mn |
| Sep 30, 2024 | 1.62 Mn |
| Jun 30, 2024 | 3.66 Mn |
| Mar 31, 2024 | 5.25 Mn |
| Dec 31, 2023 | 5.45 Mn |
| Sep 30, 2023 | 6.71 Mn |
| Jun 30, 2023 | 7.77 Mn |
| Mar 31, 2023 | 11.05 Mn |
| Dec 31, 2022 | 14.37 Mn |
| Sep 30, 2022 | 8.51 Mn |
| Jun 30, 2022 | 11.46 Mn |
| Dec 31, 2021 | 17.84 Mn |
| Sep 30, 2021 | 11.18 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Sep 30, 2020 | 8.05 Mn |
| Jun 30, 2020 | 11.89 Mn |
| Dec 31, 2019 | 21.16 Mn |